Uric acid and chronic kidney disease: which is chasing which?
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing historical, animal, and pilot human data
PubMed 23543594 · doi:10.1093/ndt/gft029
What was done
This narrative review synthesized historical perspectives, rodent experimental models, observational studies, and preliminary human clinical trials from the prior 15 years investigating the relationship between elevated serum uric acid and chronic kidney disease (CKD) progression.
What was found
The abstract reports no aggregate quantitative effect sizes. It notes that elevated serum uric acid independently predicts the development of CKD. In rat models, raising uric acid levels induced glomerular hypertension, arteriolosclerosis, glomerular injury, and tubulointerstitial fibrosis without crystal precipitation. Historical autopsy series (Talbott and Terplan) found that nearly 100% of gouty subjects had varying degrees of CKD pathology and half had impaired renal function during life. Pilot studies suggested that lowering plasma uric acid may slow renal disease progression.
Why it matters
The paper challenges the historical consensus that hyperuricemia is merely a passive marker of reduced glomerular filtration rate, repositioning uric acid as a biologically plausible, potentially modifiable driver of renal injury.
Limits
The abstract describes a narrative review without systematic search criteria, meta-analytic pooling, or formal risk-of-bias grading. Causal mechanism data derive primarily from rodent models, and human interventional data cited are limited to pilot studies with unspecified sample sizes and effect estimates.
Cited by
- supports An autopsy study from the 1960s found that over 95% of patients with gout had evidence of kidney disease.